Press ReleaseCardiawave announces positive 6-month data from its Valvosoft Pivotal Study, presented at TCT Conference ! Oct 29, 2024 READ MORE
Press ReleaseCardiawave appoints Olivier Pierron as its Chief Executive Officer Apr 16, 2024 READ MORE
Press ReleaseCardiawave annonce la nomination d’Olivier Pierron en tant que Directeur Général Apr 16, 2024 READ MORE
Press ReleaseCardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis at the 73rd Annual Conference of the ACC – April 6–8, 2024, Atlanta (GA) Apr 5, 2024 READ MORE
Press ReleaseCardiawave présentera les résultats de suivi à 30 jours de son étude pivot « Valvosoft® Pivotal Study » pour le traitement de la sténose valvulaire aortique sévère symptomatique à la 73ème Conférence annuelle de l’ACC – 6-8 avril 2024 Apr 5, 2024 READ MORE
Press ReleaseCardiawave announces the publication in The Lancet of First-In-Human clinical studies results Nov 15, 2023 READ MORE
Press ReleaseCardiawave annonce la publication dans The Lancet des résultats de ses études cliniques « First-in-Human » Nov 14, 2023 READ MORE
Press ReleaseCardiawave lauréate de la première promotion French Tech Health20 Apr 14, 2023 READ MORE
Press ReleaseCardiawave granted 3 new patents extending its intellectual property protection for its technology in the United States Feb 14, 2023 READ MORE
Press ReleaseCardiawave confirms the safety of Valvosoft®, its non-invasive ultrasound treatment for aortic stenosis. Jun 14, 2022 READ MORE
